ESMO Congress 2026

In terms of the published record, this asset corresponds to a phase III randomized trial (protocol CA017-078) captured in a conference abstract, combining neoadjuvant chemotherapy with nivolumab followed by postsurgical adjuvant nivolumab in patients with muscle-invasive bladder cancer (MIBC) ^[1]. The abstract only establishes the design positioning and provides no efficacy figures, so the actual results depend on what was disclosed at the meeting ^[1].

Abstract 4736O at ESMO26 presented exactly this phase III trial (ENERGIZE, CA017-078), reported by @AndreaNecchi, in cisplatin-eligible MIBC with 653 patients randomized. In the design, the experimental arm (n=325) received neoadjuvant nivolumab plus gemcitabine/cisplatin (GC), then radical cystectomy followed by adjuvant nivolumab; the control arm received GC then surgery. Results: event-free survival (EFS) HR 0.94, P=0.67, with no statistically significant difference between arms; pathologic complete response (pCR) rates were 39.1% vs 29.6%, numerically higher but not statistically significant. Overall survival (OS) data were truncated in the live posts and not fully disclosed; exact figures remain to be confirmed.

As of the congress, no independent news coverage of this result has been collected for this topic, so there are no figures available for cross-checking or supplementation; the above readings come solely from the live conference posts.

In terms of advancing knowledge, the results suggest that adding perioperative nivolumab on top of standard neoadjuvant GC in cisplatin-eligible MIBC does not automatically translate into a significant EFS benefit; the live commentary likewise stressed the lesson that adding immunotherapy is not automatically the same as improving outcomes. The limitations are equally clear: OS data are not fully disclosed, the pCR difference did not reach statistical significance, and key details such as follow-up duration, stratification factors, and subgroup analyses were not mentioned in the live posts, so interpretation awaits formal publication of the data.